• CGF Induces ROS-Mediated Cell Cycle Arrest in Colorectal Can

  2026-06-02

  This study characterizes the anthocyanin derivative CGF, extracted from purple sweet potato, as a potent suppressor of colorectal cancer (CRC) progression. CGF mediates its antitumor effects through ROS-driven metabolic reprogramming, mitochondrial dysfunction, and targeted disruption of cell cycle and apoptosis signaling, highlighting a promising molecular mechanism and preclinical therapeutic strategy.

• Acetoacetic Acid Sodium Salt in Advanced Energy Metabolism R

  2026-06-01

  Acetoacetic acid sodium salt (sodium 3-oxobutanoate) from APExBIO is redefining experimental workflows for diabetes and energy metabolism studies. This article delivers actionable protocols, troubleshooting insights, and cross-domain innovation, enabling researchers to achieve more reproducible and interpretable outcomes.

• SU 5402: Enhancing Cancer and Neuronal Assays with Precision

  2026-06-01

  SU 5402 empowers researchers to dissect receptor tyrosine kinase signaling with high potency, enabling advanced cancer biology and neuron-virology workflows. This article details protocol enhancements, troubleshooting, and translational use-cases for SU-5402, grounded in the latest human iPSC-derived neuron HSV-1 latency validation.

• FGFR Inhibition and ABCB1-Mediated Chemoresistance: Insights

  2026-05-31

  The referenced study demonstrates that infigratinib (BGJ 398), a pan-FGFR inhibitor, can sensitize multidrug-resistant cancer cells to chemotherapeutics by impairing ABCB1-mediated drug efflux. Notably, PD 173074, despite its potent FGFR1/VEGFR2 inhibition, does not share this chemosensitizing activity. These findings clarify distinct roles for FGFR-targeting compounds in overcoming drug resistance, informing future research and experimental tool selection.

• Dihydroartemisinin: Applied Workflows for Antimalarial & mTO

  2026-05-30

  Dihydroartemisinin, a high-purity Artemisia plant extract from APExBIO, enables robust experimental design across malaria and signaling research. This article delivers protocol enhancements, troubleshooting insights, and practical integration of the latest antiplasmodial findings to maximize data confidence.

• Technical Use of Anti-HMGB1 Rabbit Monoclonal Antibody (MA30

  2026-05-29

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) addresses the need for specific detection of HMGB1 protein in human, mouse, and rat research samples. This reagent is optimized for Western blot, immunohistochemistry, and flow cytometry, but is not validated for diagnostic or therapeutic workflows.

• LY294002: Precision PI3K Inhibition for Advanced Cancer Rese

  2026-05-29

  LY294002 offers unrivaled flexibility as both a potent PI3K/Akt/mTOR signaling pathway inhibitor and autophagy modulator, making it indispensable for dissecting cell fate mechanisms. This article delivers actionable protocols, expert troubleshooting, and translational insights, empowering researchers to extract robust, reproducible data in oncology and cell biology.

• HyperScribe T7 Cy5 RNA Labeling Kit: Precision Tools for Vir

  2026-05-28

  Explore how the HyperScribe T7 High Yield Cy5 RNA Labeling Kit enables next-generation fluorescent RNA probe synthesis for dissecting viral RNA-protein phase separation, with unique insights into assay optimization and translational research.

• Pol II Degradation Triggers Cell Death Beyond Transcription

  2026-05-28

  This article examines a recent study revealing that targeted degradation of RNA polymerase II (Pol II) initiates cell death in tumor cells independently of transcriptional inhibition. The findings refine our understanding of apoptosis induction and have practical implications for cancer research, especially in designing assays and therapeutic strategies that engage non-transcriptional cell death pathways.

• PD 173074: FGFR1/VEGFR2 Inhibition Redefines Podocyte Resear

  2026-05-27

  Explore the advanced use of PD 173074 in dissecting FGFR signaling for podocyte protection, revealing new directions in diabetic kidney disease research. This in-depth article offers practical assay guidance beyond standard cancer models.

• Applied Protocols with SU 5402: Cancer Biology & iPSC Models

  2026-05-27

  SU 5402 from APExBIO empowers researchers to dissect receptor tyrosine kinase signaling in cancer biology and advanced neuronal models. This article details workflow enhancements, troubleshooting insights, and cross-domain applications, with special attention to integrating SU 5402 into iPSC-derived sensory neuron assays.

• Phosbind Acrylamide: Enabling Quantitative Phosphorylation A

  2026-05-26

  Explore how Phosbind Acrylamide empowers precise protein phosphorylation analysis in dynamic signaling pathways—without phospho-specific antibodies. This article uniquely bridges mechanistic insights with advanced protocol optimization for challenging experimental contexts.

• Phosbind Biotin: Dinuclear Metal Complex for Phosphorylation

  2026-05-26

  Phosbind Biotin streamlines sequence-independent detection of phosphorylated proteins in Western Blot, transforming post-translational modification analysis. Its dinuclear metal complex phosphate binding mechanism offers superior sensitivity and workflow flexibility, making it ideal for high-impact studies in signal transduction and plant stress biology.

• Parathyroid Hormone (1-34) (Human): Advanced Experimental St

  2026-05-25

  Explore the advanced experimental applications of Parathyroid hormone (1-34) (human) in bone metabolism research and next-generation kidney disease modeling. This article delivers in-depth scientific insights and practical protocol guidance for leveraging this potent PTH (1-34) peptide fragment in translational studies.

• Rethinking FGFR1 Inhibition: PD 173074 in Diabetic Kidney Di

  2026-05-25

  This thought-leadership article explores the dual role of PD 173074 as a selective FGFR1/VEGFR2 inhibitor in cancer and chronic kidney disease. Integrating new mechanistic insights from FGF4-FGFR1 signaling in diabetic kidney disease (DKD), it offers translational researchers strategic guidance on leveraging PD 173074 for next-generation disease models, while critically assessing protocol design, competitive landscape, and future directions.

3614 records 12/241 page Previous Next First page 上5页 1112131415 下5页 Last page